Study identifier:D5162C00052
ClinicalTrials.gov identifier:NCT05801029
EudraCT identifier:N/A
CTIS identifier:2022-503057-18-00
A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA)
Non-small cell lung cancer (NSCLC)
Phase 2
No
Osimertinib, Amivantamab
All
80
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Osimertinib+Amivantamab Participants will receive osimertinib and amivantamab. | - |